Durable Response and Good Tolerance to the Triple Combination of Toripalimab, Gemcitabine, and Nab-Paclitaxel in a Patient With Metastatic Pancreatic Ductal Adenocarcinoma

Background: The performance of immune checkpoint inhibitor (ICI) monotherapy was proved to be disappointing in pancreatic ductal adenocarcinoma (PDAC). Increasing evidence has shown the promising efficacy of ICIs combined with systemic therapy in the first-line treatment in solid tumors. Case presen...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Front Immunol
Hlavní autoři: Shui, Lin, Cheng, Ke, Li, Xiaofen, Shui, Pixian, Li, Shuangshuang, Peng, Yang, Li, Jian, Guo, Fengzhu, Yi, Cheng, Cao, Dan
Médium: Artigo
Jazyk:Inglês
Vydáno: Frontiers Media S.A. 2020
Témata:
Immunology
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7318868/
https://ncbi.nlm.nih.gov/pubmed/32636837
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2020.01127
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky